Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTL Pharma SA

Division of Kirin Holdings Co. Ltd.
www.otl-pharma.com

Latest From OTL Pharma SA

Ex-Shire Team Builds New Euro-Specialty Group

Archimedes joins a growing new generation of pan-European specialty pharma, highlighting the need for a single commercial partner across Europe and the increasing alternatives to big and mid-sized pharma.
BioPharmaceutical Strategy

Strakan/Proskelia: Creating Long-Term Value

Symphony attempted to re-create an off-P&L financing vehicle for biotech projects that would both pass the much tougher SEC scrutiny applied since the late 1990s and allow biotechs to avoid licensing away what could be important revenue generators. To do so, it had to create a fully independent corporate vehicle with the capacity-through an alliance with an equity-incentivized CRO--to manage its own development. But its first biotech partner, Guilford Pharmaceuticals, didn't feel Symphony had proven the financing could be completely off-P&L. Consolidating the expenses, Guilford sees the deal's value largely in the additional management resources, along with the funding, that Symphony provides a second-priority program. Symphony also has yet to prove it can make its investors money from these projects: in part because the value of late-stage programs has increased since the original off-P&L vehicles were created, Symphony could only get from Guilford a single compound, not a portfolio of projects with which to reduce its investment risk.
BioPharmaceutical Strategy

Recent Dealmaking (07/2004)

Summarizing the month in European dealmaking.

Recent Dealmaking (02/2004)

Summarizing the month in European dealmaking.
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Parent & Subsidiaries
  • Kirin Holdings Co. Ltd.
  • Senior Management
  • Jean-François Labbe, Pres. & CEO
    François Anger, CFO & VP, Fin. & Admin.
    Jacques Sauzieres, VP, Scientific & Reg. Affairs
    Olivier Arnaud, VP, Bus. Dev.
    Bernard Dauvergne, VP, Mktg.
  • Contact Info
  • OTL Pharma SA
    Phone: (33) 144 885 929
    15 rue de Turbigo
    Paris, 75002
    France
Advertisement
Advertisement
UsernamePublicRestriction

Register